| Javier Narvarte, MD | |
|
670 Sierra Rose Dr, Reno, NV 89511-2072 | |
| (775) 322-4550 | |
| (775) 322-4776 |
| Full Name | Javier Narvarte |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 53 Years |
| Location | 670 Sierra Rose Dr, Reno, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326156134 | NPI | - | NPPES |
| 002046341 | Medicaid | NV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 9137 (Nevada) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sparks Dialysis (dva) | Sparks, NV | Dialysis facility |
| Renown Regional Medical Center | Reno, NV | Hospital |
| Carson Tahoe Regional Medical Center | Carson city, NV | Hospital |
| Northern Nevada Medical Center | Sparks, NV | Hospital |
| Renown South Meadows Medical Center | Reno, NV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oneill Clark Narvarte And Vicks A Professional Corporation | 2668448531 | 28 |
News Archive
Uroplasty, Inc. announced today that the underwriters for the recently announced public offering of Uroplasty common stock have exercised in full their over-allotment option to purchase an additional 600,000 shares of the Company's common stock. The 4,600,000 shares of Uroplasty common stock in the offering, including the 600,000 shares subject to the over-allotment option, are being sold at a price to the public of $3.50 per share.
MedRisk, Inc. announced today that it has been awarded the HIPAA Privacy and HIPAA Security Accreditations from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry.
Certain mutations of the gene ATRX were associated with age at diagnosis in children and young adults with advanced-stage neuroblastoma, a cancer that grows in parts of the nervous system, according to a study in the March 14 issue of JAMA.
Patients prescribed opioid pain medications whose doses varied over time were 3 times more likely to experience an overdose than patients prescribed stable opioid doses, according to an observational study from Kaiser Permanente published today in JAMA Network Open.
Their method uses "Cellular Analysis and Notification of Antigen Risks and Yields" (CANARY) cells, which are immune-system cells engineered to contain a fluorescent protein naturally found in jellyfish. CANARY cells have the immune system's ability to detect specific disease-causing agents, lighting up when they recognize a pathogen.
› Verified 8 days ago
| Entity Name | Oneill Clark Narvarte & Vicks A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962501940 PECOS PAC ID: 2668448531 Enrollment ID: O20040902000894 |
News Archive
Uroplasty, Inc. announced today that the underwriters for the recently announced public offering of Uroplasty common stock have exercised in full their over-allotment option to purchase an additional 600,000 shares of the Company's common stock. The 4,600,000 shares of Uroplasty common stock in the offering, including the 600,000 shares subject to the over-allotment option, are being sold at a price to the public of $3.50 per share.
MedRisk, Inc. announced today that it has been awarded the HIPAA Privacy and HIPAA Security Accreditations from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry.
Certain mutations of the gene ATRX were associated with age at diagnosis in children and young adults with advanced-stage neuroblastoma, a cancer that grows in parts of the nervous system, according to a study in the March 14 issue of JAMA.
Patients prescribed opioid pain medications whose doses varied over time were 3 times more likely to experience an overdose than patients prescribed stable opioid doses, according to an observational study from Kaiser Permanente published today in JAMA Network Open.
Their method uses "Cellular Analysis and Notification of Antigen Risks and Yields" (CANARY) cells, which are immune-system cells engineered to contain a fluorescent protein naturally found in jellyfish. CANARY cells have the immune system's ability to detect specific disease-causing agents, lighting up when they recognize a pathogen.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Javier Narvarte, MD 670 Sierra Rose Dr, Reno, NV 89511-2072 Ph: (775) 322-4550 | Javier Narvarte, MD 670 Sierra Rose Dr, Reno, NV 89511-2072 Ph: (775) 322-4550 |
News Archive
Uroplasty, Inc. announced today that the underwriters for the recently announced public offering of Uroplasty common stock have exercised in full their over-allotment option to purchase an additional 600,000 shares of the Company's common stock. The 4,600,000 shares of Uroplasty common stock in the offering, including the 600,000 shares subject to the over-allotment option, are being sold at a price to the public of $3.50 per share.
MedRisk, Inc. announced today that it has been awarded the HIPAA Privacy and HIPAA Security Accreditations from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry.
Certain mutations of the gene ATRX were associated with age at diagnosis in children and young adults with advanced-stage neuroblastoma, a cancer that grows in parts of the nervous system, according to a study in the March 14 issue of JAMA.
Patients prescribed opioid pain medications whose doses varied over time were 3 times more likely to experience an overdose than patients prescribed stable opioid doses, according to an observational study from Kaiser Permanente published today in JAMA Network Open.
Their method uses "Cellular Analysis and Notification of Antigen Risks and Yields" (CANARY) cells, which are immune-system cells engineered to contain a fluorescent protein naturally found in jellyfish. CANARY cells have the immune system's ability to detect specific disease-causing agents, lighting up when they recognize a pathogen.
› Verified 8 days ago
Dr. Richard Bruce Rosen, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 781 Mill St, Reno, NV 89502 Phone: 775-398-1980 Fax: 775-398-1981 | |
Rahul Navin Mediwala, Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1500 E 2nd St, Suite 201, Reno, NV 89502 Phone: 775-982-3355 Fax: 775-982-3356 | |
Dr. Raymond Hill Scott Iii, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 330 Crampton St, Reno, NV 89502 Phone: 775-336-3700 Fax: 775-336-3701 | |
Dr. Bruce William Denney, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1155 Mill St Ms W14, Reno, NV 89502 Phone: 775-982-7878 Fax: 775-982-4196 | |
Dr. Elmer Epres Alegre, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1715 Kuenzli St, Reno, NV 89502 Phone: 775-329-5162 Fax: 775-334-4356 | |
Dr. Devang Mahesh Desai, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 645 N Arlington Ave Ste 555, Reno, NV 89503 Phone: 775-770-7622 Fax: 775-770-3683 | |
Dr. Louis Christopher Tripoli, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 1510 Meadow Wood Ln, Prominence Health, Reno, NV 89502 Phone: 775-770-9242 Fax: 928-832-2864 |